TMDI - TMDI STOCK NEWS

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD) announced the completion of pre-clinical studies for its Enos™ robotic surgical system, adhering to FDA's good laboratory practice (GLP) regulations. The studies involved hysterectomies in porcine subjects. Results are anticipated in the coming months, impacted by COVID-19-related delays. More than 70 procedures across multiple subspecialties were conducted. CEO David McNally expressed optimism about progressing towards regulatory submissions and clinical studies, reaffirming the focus on gynecologic surgical applications.

Titan Medical Inc. (Nasdaq: TMDI) announced that President and CEO David McNally will present at two investor conferences: the Oppenheimer Virtual Fall Healthcare Life Sciences & Med Tech Summit on September 21, 2021, and the Cantor Virtual Global Healthcare Conference on September 27, 2021. The company focuses on robotic single access surgery technology, specifically its Enos™ surgical system. Webcasts of the presentations will be available on the company's website.

Titan Medical Inc. (NASDAQ: TMDI) announced that President and CEO David McNally will present the company's Enos™ robotic single access surgical system at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13, 2021, at 7:00 a.m. ET. The presentation will be available for on-demand viewing via the company's website. Titan Medical focuses on advancing robotic surgery technologies, with a vision to initially target gynecologic surgical indications. The company retains worldwide rights to commercialize its robotic technologies, including a license agreement with Medtronic.

Titan Medical Inc. (Nasdaq: TMDI) reported financial results for the second quarter and first half of 2021, marking significant advancements in its surgical technology for robotic single access surgery. The company increased cash reserves to $55 million, driven by a $10 million license payment from Medtronic. R&D expenses surged to $7.1 million for the quarter, up from $0.1 million year-over-year, reflecting intensified product development efforts. Progress has been made toward filing an IDE application with the FDA, expected in Q1 2022, and the company has strengthened its Board of Directors.

Titan Medical Inc. (NASDAQ: TMDI; TSX: TMD) has announced it will issue its second quarter 2021 financial results before market open on August 11, 2021. An investor audio webcast will follow at 8:30 a.m. ET, featuring CEO David McNally and CFO Stephen Lemieux discussing the results and business highlights. The company specializes in robotic single access surgery technologies, with a focus on developing the Enos™ system for gynecologic surgeries. Titan retains worldwide rights to its technologies licensed to Medtronic plc.

Titan Medical Inc. (TMDI), a company focusing on robotic surgical technologies, has appointed Tammy Carrea as Vice President of Quality and Regulatory Affairs. With over 25 years in the medical device industry, Carrea's expertise in regulatory strategies and FDA inspections is expected to enhance Titan's efforts towards human clinical studies for the Enos™ surgical system. Her appointment follows the departure of past VP Curtis Jensen, who left to pursue other opportunities. Titan aims to submit an Investigational Device Exemption application to the FDA.

Titan Medical Inc. (Nasdaq:TMDI; TSX:TMD) announced that leadership, including President and CEO David McNally and CFO Stephen Lemieux, will engage with investors at the Alliance Global Partners Virtual MedTech Summer Investor Conference on July 29, 2021. Titan Medical focuses on developing robotic surgical technologies, particularly the Enos™ system, aimed at enhancing gynecologic surgeries. The company retains worldwide commercialization rights for its technologies licensed to Medtronic. Titan's innovations emphasize ergonomic design and increased surgeon dexterity.

Titan Medical Inc. (Nasdaq:TMDI; TSX:TMD) announced the appointment of Stephen Lemieux as Chief Financial Officer, effective immediately. Lemieux brings over 18 years of experience in healthcare firms and has led transactions exceeding $400 million. He succeeds Monique Delorme, who will aid in the transition until March 2022. The company emphasizes its innovative commitment to robotic surgery, especially with the Enos system, which is approaching key milestones. Lemieux aims to leverage his financial expertise to support Titan's growth strategy.

Titan Medical Inc. (TMDI) held its Annual and Special Meeting on June 9, 2021, where all management nominees were elected as directors by shareholders. A total of 56,098,112 out of 109,527,690 common shares were voted. Paul Cataford welcomed Cathy Steiner to the board, noting her extensive experience in healthcare investment banking. Shareholders also approved BDO Canada LLP as independent auditors and renewed the Stock Option Plan. Titan Medical continues to focus on its Enos™ system for robotic single access surgery, primarily targeting gynecologic applications.